3 Dec 2019 The FDA and the American public have recently been seeking clarification on how FDA oversight applies to CBD products. 2 Dec 2019 In late November, the FDA issued 15 warning letters to CBD like CBD, we'll continue to monitor the marketplace and take action as needed 5 Dec 2019 Seyfarth Synopsis: In its largest mass enforcement action involving cannabidiol (CBD) yet, the U.S. Food & Drug Administration (FDA) 26 Nov 2019 25 November 2019 Food and Drug Administration FDA issued warning CBD Update: FDA Takes More Aggressive Enforcement Action in 13 Jan 2020 But in the case of the unregulated cannabidiol market, there's one federal action that this large majority of voters want: better regulation. Despite
29 Nov 2019 “The decision by the FDA to send 15 new warning letters and remind consumers of potential harm caused by untested and illegal CBD is a step
The FDA’s approach to Hemp-CBD has been one of regulatory inaction and even obfuscation. Rather than providing guidance to or issuing regulations concerning manufacturers of Hemp-CBD products, the FDA has focused on telling consumers and Hemp-CBD businesses that most Hemp-CBD products are not legal and not safe. This latest round of warning
3 Jan 2020 A spate of new class-action lawsuits threaten the CBD industry. A group of remorseful CBD users is suing to test that theory, and it's going after Juul and other e-cig makers to Congress: FDA, not you, should regulate us.
“It started with class-action suits against two major CBD companies in California and has hit at least six altogether.” The Perkins Coie law firm warned, “Manufacturers of CBD products should be aware of the likelihood of increased litigation, especially class actions, resulting from the FDA’s recent actions. CBD Update: FDA Takes More Aggressive Enforcement Action in Keller and Heckman advises clients regularly on the status of CBD in FDA-regulated products. We will continue to monitor FDA’s development of a potential regulatory framework and the direction of additional enforcement action to assess the risks and opportunities for companies marketing these types of products. CBD In Food And Beverage: 3 Developments To Watch In 2020 Class Action Litigation: Given the ambiguity around applicable rules surrounding CBD-containing products, particularly those in the food and beverage industry, private party litigation is expected CBD industry hit with nearly half dozen class action lawsuits | FDA’s recent batch of warning letters reiterated a position taken by the agency since at least 2015: that CBD cannot be marketed in a dietary supplement because, in short, the compound was first studied as a drug by GW Pharmaceuticals plc, whose CBD medicine Epidiolex was approved by FDA in 2018. And for years in warning letters, the agency has expressed concerns about CBD marketers making claims that their products can treat diseases like cancer.
2 days ago “I think it would also be useful to argue that FDA has actually not taken final agency action on the CBD issue. A Warning Letter is not final
2 Dec 2019 In late November, the FDA issued 15 warning letters to CBD like CBD, we'll continue to monitor the marketplace and take action as needed 5 Dec 2019 Seyfarth Synopsis: In its largest mass enforcement action involving cannabidiol (CBD) yet, the U.S. Food & Drug Administration (FDA)